Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5252W HIGH $12.10
Volume
255.56 K
Value Traded
744.13 K
Short % Float
19.78%
-15.38%Week
-30.11%1 Month
-43.65%3 Month
-53.49%6 Month
-78.64%5 Year
-78.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
66.27 M
EPS (TTM)
-1.44
P/E Ratio
-
Ent. Value
64.30 M
Total Shares
26.19 M
Float Shares
2.64 M
Insiders
90.84%
Institutions
10.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NTHI Catalyst Timeline
Dated clinical, regulatory and corporate events for NeOnc Technologies Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NeOnc Technologies Holdings, Inc.
163Total events
21Upcoming
36Tier-1 (high impact)
2025 to 2038Coverage
Upcoming catalysts 2
Event history 50
▲Management ChangeCorporate
CEO Amir F. Heshmatpour purchased 37,000 shares at weighted-average $3.6654
▲Quarterly UpdateCorporate
NeOnc redeems all 6,000 outstanding Series A preferred shares for $6 million
▲Topline ReadoutNEO100Clinical Data
NEO100 Phase 2a topline results reported
recurrent IDH1-mutant high-grade gliomasource ↗
▲Topline ReadoutNEO100Clinical Data
Phase 2a topline results for NEO100 reported
recurrent IDH1-mutant high-grade gliomasource ↗
▲Management ChangeCorporate
Director Thomas Chen reported purchases of 33,787 shares on August 14 and 2,472 shares on August 17
▲Topline ReadoutNEO100Clinical Data
NeOnc reported topline results from Phase 2a portion of NEO100-01
recurrent or progressive Grade III and Grade IV IDH1-mutant gliomasource ↗
◆Oral PresentationNEO100Presentation
Investor conference call to discuss topline Phase 2a results for NEO100
Recurrent IDH1-Mutant High-Grade Gliomasource ↗
▲Primary Endpoint MetNEO100Clinical Data
Phase 2a primary endpoint (six-month PFS) met vs prespecified historical benchmark
recurrent or progressive Grade III and Grade IV IDH1-mutant gliomasource ↗
▲Full ResultsNEO100Clinical Data
Reported median overall survival of 26.09 months and survival rates at 6, 12, 24 months
recurrent IDH1-mutant high-grade gliomasource ↗
▲Safety Data UpdateNEO100Clinical Data
Reported no major toxicities across Phase 2a cohort
recurrent IDH1-mutant high-grade gliomasource ↗
▲Other Regulator MilestoneNEO100Ex-US Regulatory
Second IND authorization from Department of Health – Abu Dhabi
recurrent high-grade gliomassource ↗
▲Management ChangeCorporate
CEO Amir Heshmatpour open-market share purchases including 15,000 shares in August
◆Type B MeetingNEO100FDA Meeting
NeOnc intends to request Type B meeting with FDA on registrational path for NEO100
recurrent or progressive high-grade IDH1-mutant gliomasource ↗
▲Topline ReadoutNEO100Clinical Data
Topline Phase 2a results for NEO100 in recurrent/progressive IDH1-mutant glioma
recurrent or progressive Grade III and Grade IV IDH1-mutant gliomasource ↗
▲Primary Endpoint MetNEO100Clinical Data
NEO100 Phase 2a study met its primary endpoint
recurrent or progressive IDH1-mutant high-grade gliomasource ↗
▲FDA Feedback ReceivedNEO212FDA Meeting
FDA written feedback on NEO212 CMC development and capsule-to-tablet transition
malignant brain tumors and other central nervous system cancerssource ↗
●End Of Phase 1 MeetingNEO212FDA Meeting
Type B End-of-Phase 1 meeting scheduled for July 9, 2026, then canceled
malignant brain tumors and other central nervous system cancerssource ↗
●End Of Phase 2 MeetingNEO212FDA Meeting
Type B End-of-Phase 1 meeting scheduled for July 9, 2026, then canceled after FDA written feedback
malignant brain tumors and other central nervous system cancerssource ↗
◆Topline ReadoutNEO100Clinical Data
Topline results from NEO100-01 Phase 2a trial
recurrent IDH1-mutant high-grade gliomasource ↗
●FDA Feedback ReceivedNEO212FDA Meeting
NeOnc reports FDA feedback on chemistry, manufacturing and controls for NEO212
central nervous system cancerssource ↗
▲IND ClearanceNEO212IND
Abu Dhabi IND authorization for NEO212
aggressive brain tumors, including glioblastomasource ↗
▲Primary CompletionNEO212Trial
Phase 1 dose-escalation study completed
aggressive brain tumors, including glioblastomasource ↗
▲Enrollment CompleteNEO100Trial
Phase 2a study enrollment completed
recurrent IDH1-mutant high-grade glioma and related brain cancerssource ↗
▲IND ClearanceNEO212IND
Department of Health – Abu Dhabi granted IND authorization for NEO212
aggressive brain tumorssource ↗
▲Enrollment CompleteNEO100Trial
Full enrollment achieved in Phase 2a study of NEO100
recurrent IDH1-mutant high-grade glioma and related brain cancerssource ↗
▲Primary CompletionNEO212Trial
Phase 1 dose escalation completed, RP2D selected at 610 mg
recurrent glioblastoma and brain metastasessource ↗
●Dose Finding UpdateNEO212Trial
Completion of Phase 1 dose escalation and selection of 610 mg as recommended Phase 2 dose for NEO212
▲IND ClearanceNEO100IND
UAE IND authorization for NEO100 covering three adult programs and pediatric development
adult programs ranging from Phase 1 through Phase 2, as well as pediatric developmentsource ↗
▲Trial Authorization (CTA / IND)NEO100Ex-US Regulatory
UAE IND approval for NEO100
adult and pediatric development programssource ↗
▲Trial Authorization (CTA / IND)NEO212Ex-US Regulatory
UAE IND approval for NEO212
adult and pediatric development programssource ↗
▼Equity OfferingCorporate
NeOnc issues Series A Convertible Preferred Stock in private placement for $5.0 million gross proceeds
◆Topline ReadoutNEO100Clinical Data
Full data readout six months post-enrollment
recurrent WHO Grade III/IV IDH1-mutant astrocytomasource ↗
Past FDA Catalysts and PDUFA Decisions
How NTHI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-31 | NEO100 | Phase 2a interim results | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 88%
Micro Cap(rank 579 of 658)
Percentile Rank
NeOnc Technologies Holdings, Inc. faces pipeline headwinds (23/100), with $70M risk-adjusted pipeline value, led by NEO100 in Glioblastoma Multiforme (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEO100 Small moleculeNCT05023018 | Residual, Progressive or Recurrent Grade II or III Meningioma | Phase 2 | RECRUITING | 30 | Jun 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every NTHI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NEO100 Fast TrackOrphanRare Pediatric | recurrent or progressive Grade III and Grade IV IDH1-mutant glioma | Phase 2a | 2026-09-29 | six-month progression-free survival of 48.9% versus a prespecified 20% benchmark (p=0.0047); median overall survival of 26.09 months; 86.7% of patients were alive at six months; five of 24 patients remained on treatment at the data cutoff; one partial response remained ongoing beyond 114 daysRead More | NeOnc’s Powerful Brain Cancer Pipeline AdvancesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Heshmatpour Amir FDirector, Officer (CEO, President), 10% Owner | Buy | 35,000 3,183,000 held | $3.30 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NTHI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NTHI for Q2 2026. | ||||
NTHI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NTHI ranks across every disease it competes in
Competitive Position is a premium feature
See how NTHI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNTHI News
NTHI▼ -6.6%today
NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
NeOnc Technologies Holdings (NTHI) is gaining attention as it prepares for FDA discussions regarding its brain-cancer therapies NEO100 and NEO212. With a recent positive clinical trial outcome for NEO100 and upcoming regulatory meetings, the company is positioned for potential growth. Analysts are optimistic, with multiple Buy ratings highlighting the company's development strategy and market potential.
Read more →NTHINeOnc’s Powerful Brain Cancer Pipeline Advances
NeOnc Technologies Holdings is preparing for a significant FDA meeting on November 17, 2026, regarding its NEO212 treatment for aggressive CNS cancers. The company aims to discuss trial design and potential accelerated approval pathways. NEO212 has shown promising early results, while NeOnc's NEO100 program also reported positive Phase 2a outcomes. The upcoming meeting is crucial for the company's development strategy.
Read more →NTHIPowerful NeOnc Brain Cancer Pipeline Advances
NeOnc Technologies Holdings is preparing for a pivotal FDA meeting on November 17, 2026, regarding its brain cancer drug NEO212. The company aims to discuss trial design and potential pathways for accelerated approval based on preliminary Phase 1 data. The meeting is seen as a critical point for NeOnc's development strategy, with investors closely monitoring the outcomes.
Read more →NTHINeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
NeOnc Technologies announced an FDA End-of-Phase 1 meeting for NEO212 on November 17, 2026. The meeting will focus on the clinical development program, including trial design and patient population. Encouraging results were reported in Phase 1, with notable responses in patients with recurrent glioblastoma and lung cancer with brain metastases. The company aims to discuss potential accelerated approval pathways.
Read more →NTHINeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst
NeOnc Technologies Holdings has gained new Wall Street coverage as it advances its brain-cancer pipeline. Analyst Jonathan Aschoff from Roth Capital highlights promising Phase 2a results for NEO100, which exceeded benchmarks for progression-free survival. The company plans to engage the FDA regarding a registrational path and has strengthened its financial position with a recent capital raise.
Read more →NTHINeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier
NeOnc Technologies Holdings is advancing brain cancer treatment with NEO100, an intranasal delivery system targeting IDH1-mutant gliomas. The Phase 2a study reported a 48.9% six-month progression-free survival, surpassing the benchmark. While no major toxicities were observed, the company faces the challenge of validating these results in larger studies. A Type B meeting with the FDA is planned to discuss the drug's regulatory pathway.
Read more →NTHINeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc Technologies Holdings' NEO100, an intranasal formulation, has shown promising results in a Phase 2a study for recurrent high-grade glioma. The study reported a six-month progression-free survival of 48.9%, significantly above the benchmark. The innovative delivery method aims to bypass the blood-brain barrier, potentially changing treatment logistics for patients. However, further validation in larger studies is necessary to confirm these findings.
Read more →NTHI▲ +14%on this newsshared move
NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates
NeOnc Technologies has redeemed all outstanding Series A Convertible Preferred Stock, eliminating potential dilution for shareholders. This move follows a $15 million registered direct offering, providing fresh capital for the company's clinical-stage programs. NeOnc is advancing its CNS cancer pipeline, with promising results from NEO100 and progress in NEO212.
Read more →NTHI▲ +14%on this newsshared move
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
NeOnc Technologies has redeemed all 6,000 shares of its Series A Convertible Preferred Stock for cash, totaling $6 million. This action eliminates potential dilution for shareholders and simplifies the company's capital structure. The redemption was funded through proceeds from a recent $15 million offering. NeOnc continues to advance its clinical programs, NEO100 and NEO212, in Phase II trials.
Read more →NTHI▼ -9.7%on this newsshared move
NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
NeOnc Technologies Holdings (NTHI) executives have invested approximately $629,000 in open-market purchases following promising Phase 2a results for their brain-cancer therapy, NEO100. The study achieved a six-month progression-free survival rate of 48.9%, surpassing the 20% benchmark. The company also announced a $15 million offering to support its clinical programs, positioning itself at a critical juncture for future development.
Read more →NTHI▼ -9.7%on this newsshared move
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
NeOnc Technologies Holdings, Inc. announced that executives have invested approximately $629,000 in open-market stock purchases following positive Phase 2a results for NEO100. CEO Amir Heshmatpour has personally invested over $1.5 million in NeOnc shares over the past year. The Phase 2a study showed a six-month progression-free survival rate of 48.9%, significantly exceeding the benchmark.
Read more →NTHI▼ -7.2%on this newsshared move
Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
NeOnc Technologies Holdings' CEO has increased his investment following a $15 million financing round aimed at advancing novel therapies for brain cancer. The company reported promising results from its Phase 2a study of NEO100, showing a six-month progression-free survival rate of 48.9%. NeOnc's innovative delivery methods may enhance patient quality of life, although both therapies are still investigational and require further regulatory review.
Read more →NTHIInsiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
NeOnc Technologies Holdings (NTHI) has seen significant insider buying, with CEO Amir Heshmatpour purchasing 37,000 shares. This comes after the company reported promising Phase 2a results for NEO100 in treating recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate. NeOnc plans to engage with the FDA to discuss the potential registrational path for NEO100, which could be a pivotal moment for the company.
Read more →NTHINeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
NeOnc Technologies Holdings has raised $15 million through a registered direct offering, attracting institutional investors. The financing coincides with positive Phase 2a results for NEO100, showing a 48.9% progression-free survival rate. Insider purchases by executives further bolster investor confidence. The company plans to meet with the FDA to discuss a potential registrational pathway for NEO100.
Read more →NTHI▼ -11.1%on this newsshared move
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
NeOnc Technologies Holdings, Inc. has announced the pricing of a $15 million registered direct offering under Nasdaq rules. The offering is targeted at both new and existing institutional investors. This funding is expected to bolster the company's efforts in developing therapies for central nervous system cancers.
Read more →NTHI▼ -19.1%on this newsshared move
NeOnc' Phase 2 Data Could Put Cancer on the Ropes
NeOnc Technologies Holdings has reported promising results from its Phase 2a study of NEO100 for treating recurrent or progressive Grade III and IV IDH1-mutant glioma. The study showed a six-month progression-free survival rate of 48.9%, significantly exceeding the benchmark. The company plans to engage with the FDA to discuss a potential registrational pathway, marking a pivotal moment for its clinical development.
Read more →NTHINeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
NeOnc Technologies Holdings reported positive topline results from its Phase 2a study of NEO100 for recurrent glioma, achieving a six-month progression-free survival of 48.9%. The company plans to request a Type B meeting with the FDA to discuss a potential registrational pathway. While the results are promising, they do not guarantee approval, and the study's open-label design presents limitations.
Read more →NTHINeOnc’s Clinical Story Is Now the Main Event
NeOnc Technologies Holdings has reported positive Phase 2a results for NEO100 in treating recurrent Grade III and IV IDH1-mutant glioma, achieving a six-month progression-free survival of 48.9%. The company plans to request a Type B meeting with the FDA to discuss a potential regulatory pathway. While the results are promising, risks remain in the development process.
Read more →NTHINeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
NeOnc Technologies' CEO, Amir Heshmatpour, has increased his stake in the company by purchasing 15,000 shares following positive results from the NEO100 Phase 2a trial. The trial demonstrated a 48.9% six-month progression-free survival rate, significantly surpassing historical benchmarks. This insider buying, combined with a substantial short interest in the stock, suggests a potential shift in market dynamics as investors reassess the company's value.
Read more →NTHI▲ +16.4%on this news· ran to +31% by day 1shared move
NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc Technologies Holdings (NTHI) has reported promising Phase 2a results for NEO100 in treating recurrent IDH1-mutant high-grade glioma, achieving a six-month progression-free survival rate of 48.9%. This outcome significantly surpasses the historical benchmark of 20%. The results enhance NTHI's capital-raising potential via its Nasdaq listing, allowing the company to leverage clinical success for future financing.
Read more →About NeOnc Technologies Holdings, Inc.
Headquarters23975 PARK SORRENTO, CALABASAS, CA, 91302
BIOPHARMAWATCH ELITE PLUS
Trade the next NTHI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime